Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

EudraCT 2018-000978-30

31 evidence topics · 1 source

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Group preparation, simultaneous administration session, and integration

“During this visit, participants attended a 2-h group preparatory session (involving all participants to be dosed the following day, a lead therapist and assisting therapists) and had a short (5–15 min) individual discussion with their assigned assisting therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Administration sessions generally lasted ~6–8 h, with psychological support available throughout from specially trained assisting therapists, who were supervised by a lead therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The simultaneous dosing involved each participant having a private space, for example, a bed separated by curtains within the same room, so they could focus on their own experience with minimal distractions, especially as participants were encouraged to wear eyeshades, earplugs and/or earphones for the duration of the administration session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants were subsequently discharged and asked to return the following day (day 1; visit 4) for safety assessments and a discussion with their allocated therapist about the subjective experience during the administration session (integration session).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study outcomes
Rationale for using CANTAB cognitive measures as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Participant demographics, safety population
CharacteristicPsilocybin 25 mg (N = 30)Psilocybin 10 mg (N = 30)Placebo (N = 29)Overall (N = 89)
Male, n (%)“16 (53.3)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“16 (55.2)”View highlighted excerpt for this quote“48 (53.9)”View highlighted excerpt for this quote
Female, n (%)“14 (46.7)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“13 (44.8)”View highlighted excerpt for this quote“41 (46.1)”View highlighted excerpt for this quote
White, n (%)“25 (83.3)”View highlighted excerpt for this quote“27 (90.0)”View highlighted excerpt for this quote“20 (69.0)”View highlighted excerpt for this quote“72 (80.9)”View highlighted excerpt for this quote
Age at consent, years, mean (SD)“36.6 (10.29)”View highlighted excerpt for this quote“36.1 (9.25)”View highlighted excerpt for this quote“35.6 (7.69)”View highlighted excerpt for this quote“36.1 (9.06)”View highlighted excerpt for this quote
BMI, kg/m2, mean (SD)“22.9 (3.75)”View highlighted excerpt for this quote“23.0 (2.90)”View highlighted excerpt for this quote“23.7 (3.20)”View highlighted excerpt for this quote“23.2 (3.29)”View highlighted excerpt for this quote
Undergraduate or higher national diploma, n (%)“9 (30.0)”View highlighted excerpt for this quote“11 (36.7)”View highlighted excerpt for this quote“10 (34.5)”View highlighted excerpt for this quote“30 (33.7)”View highlighted excerpt for this quote
Master’s or postgraduate diploma, n (%)“16 (53.3)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“15 (51.7)”View highlighted excerpt for this quote“47 (52.8)”View highlighted excerpt for this quote
PhD, n (%)“3 (10.0)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“4 (13.8)”View highlighted excerpt for this quote“9 (10.1)”View highlighted excerpt for this quote
Prior psilocybin experience, n (%)“11 (36.7)”View highlighted excerpt for this quote“15 (50.0)”View highlighted excerpt for this quote“7 (24.1)”View highlighted excerpt for this quote“33 (37.1)”View highlighted excerpt for this quote
Efficacy results
CANTAB measures: least squares mean difference from placebo
CANTAB measure and doseDay 8, LS mean (95% CI) difference from placeboDay 29, LS mean (95% CI) difference from placebo
Global composite, 10 mg“−0.1960 (−0.39172, −0.00024)”View highlighted excerpt for this quote“0.0364 (−0.21234, 0.28505)”View highlighted excerpt for this quote
Global composite, 25 mg“−0.1167 (−0.31228, 0.07898)”View highlighted excerpt for this quote“0.1519 (−0.09846, 0.40219)”View highlighted excerpt for this quote
PAL-TEA, 10 mg“2.5 (−0.57, 5.65)”View highlighted excerpt for this quote“−2.4 (−6.48, 1.59)”View highlighted excerpt for this quote
PAL-TEA, 25 mg“−0.5 (−3.60, 2.60)”View highlighted excerpt for this quote“−2.5 (−6.59, 1.52)”View highlighted excerpt for this quote
SWM-BE, 10 mg“1.5 (−1.27, 4.27)”View highlighted excerpt for this quote“1.7 (−0.56, 4.02)”View highlighted excerpt for this quote
SWM-BE, 25 mg“1.7 (−1.02, 4.51)”View highlighted excerpt for this quote“0.5 (−1.83, 2.77)”View highlighted excerpt for this quote
SWM-S, 10 mg“0.4 (−0.46, 1.26)”View highlighted excerpt for this quote“0.2 (−0.78, 1.16)”View highlighted excerpt for this quote
SWM-S, 25 mg“0.3 (−0.59, 1.12)”View highlighted excerpt for this quote“−0.4 (−1.35, 0.60)”View highlighted excerpt for this quote
RVP-A’, 10 mg“−0.0017 (−0.00984, 0.00651)”View highlighted excerpt for this quote“0.0103 (−0.00464, 0.02524)”View highlighted excerpt for this quote
RVP-A’, 25 mg“−0.0053 (−0.01348, 0.00286)”View highlighted excerpt for this quote“0.0099 (−0.00519, 0.02490)”View highlighted excerpt for this quote
Social cognition and emotional processing scales: least squares mean difference from placebo
Scale and doseDay 8, LS mean (95% CI) difference from placeboDay 85, LS mean (95% CI) difference from placebo
PET, 10 mg“−0.1 (−0.39, 0.15)”View highlighted excerpt for this quote“−0.1 (−0.39, 0.15)”View highlighted excerpt for this quote
PET, 25 mg“0.2 (−0.11, 0.42)”View highlighted excerpt for this quote“0.1 (−0.12, 0.41)”View highlighted excerpt for this quote
RMET, 10 mg“0.1 (−1.43, 1.69)”View highlighted excerpt for this quote“0.2 (−1.53, 1.95)”View highlighted excerpt for this quote
RMET, 25 mg“0.2 (−1.44, 1.74)”View highlighted excerpt for this quote“0.5 (−1.29, 2.28)”View highlighted excerpt for this quote
SSR Global, 10 mg“1.2 (−2.16, 4.56)”View highlighted excerpt for this quote“0.3 (−2.83, 3.49)”View highlighted excerpt for this quote
SSR Global, 25 mg“2.8 (−0.50, 6.18)”View highlighted excerpt for this quote“2.2 (−0.94, 5.29)”View highlighted excerpt for this quote
SVO Angle, 10 mg“3.4 (−0.05, 6.85)”View highlighted excerpt for this quote“3.4 (−0.16, 6.97)”View highlighted excerpt for this quote
SVO Angle, 25 mg“2.1 (−1.32, 5.58)”View highlighted excerpt for this quote“2.4 (−1.16, 6.06)”View highlighted excerpt for this quote
TEQ, 10 mg“0.1 (−0.16, 0.31)”View highlighted excerpt for this quote“0.1 (−0.15, 0.34)”View highlighted excerpt for this quote
TEQ, 25 mg“0.2 (−0.08, 0.38)”View highlighted excerpt for this quote“0.1 (−0.13, 0.36)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Most frequent treatment-emergent adverse events and events of special interest, safety population
TEAE (MedDRA preferred term)25 mg, n (%)25 mg, events10 mg, n (%)10 mg, eventsPlacebo, n (%)Placebo, events
Hallucination, visual“21 (70.0)”View highlighted excerpt for this quote“22”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“20”View highlighted excerpt for this quote“2 (6.9)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Illusion“18 (60.0)”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“19 (63.3)”View highlighted excerpt for this quote“25”View highlighted excerpt for this quote“4 (13.8)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Mood altered“15 (50.0)”View highlighted excerpt for this quote“25”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“23”View highlighted excerpt for this quote“6 (20.7)”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote
Headache“15 (50.0)”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“9 (30.0)”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“5 (17.2)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Fatigue“8 (26.7)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“9 (30.0)”View highlighted excerpt for this quote“10”View highlighted excerpt for this quote“3 (10.3)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Euphoric mood“7 (23.3)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Tension headache“6 (20.0)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“3 (10.0)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3 (10.3)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Time perception altered“6 (20.0)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3 (10.3)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Emotional disorder“5 (16.7)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Somatic hallucination“5 (16.7)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“8 (26.7)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“4 (13.8)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Affect lability“3 (10.0)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“1 (3.4)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Any TEAE of special interest“26 (86.7)”View highlighted excerpt for this quote“80”View highlighted excerpt for this quote“25 (83.3)”View highlighted excerpt for this quote“81”View highlighted excerpt for this quote“10 (34.5)”View highlighted excerpt for this quote“19”View highlighted excerpt for this quote
Substance-induced psychotic disorder“1 (3.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Study limitations
Summary: healthy participants, exploratory sample size, blinding not assessed, practice effects, sponsor involvement

The study enrolled 89 healthy participants who were typically highly educated, and 37% of the sample had previous psilocybin experience; the authors state that these factors and the small sample size could have limited generalisability and that the findings warrant investigation in clinical populations. The sample size was not powered to detect statistically significant differences, and p values were not reported. Blinding efficacy was not assessed, and the authors state that participants may have been able to determine their assigned treatment group. Practice effects could have influenced results, and outcomes were measured at day 8 and at day 29 or 85. The study was funded and sponsored by COMPASS Pathways, and several authors are employees or former employees of the company.